ag凯发k8真人娱乐最新网址

ag凯发k8真人娱乐最新网址, at Upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in November

- NEObody technology platform enables dynamic targeting of a distinct epitope of CTLA-4 for enhanced safety and efficacy -
- Data from phase 1b/2 studies in heavily pre-treated patients showcase differentiated safety profile of黄金城游戏 across dosing levels, with repeat dosing both as monotherapy and in combination with anti-PD-1 therapy -
- Posters include new details of responses in monotherapy and combination therapy in tumor types where current anti-CTLA-4 therapy is not approved -

SAN DIEGO and SUZHOU, China, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that it will present clinical data from phase 1b/2 studies of its anti-CTLA-4 antibody candidate,黄金城游戏, at the upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting taking place November 8-12 in Boston.

The posters will summarize the comprehensive safety data for黄金城游戏 with repeat dosing as monotherapy, as well as new data supporting its optimal dose selection in combination with two different anti-PD-1 therapies. Additionally, data will show anti-tumor activity in warm and cold tumors, including details of a partial response with monotherapy and a complete response in combination therapy, which were both observed in tumor types where no anti-CTLA-4 therapy is approved.

Details for the poster presentations include:
. Title: A Phase 1b/2 Study of a Novel Anti-CTLA-4 NEObody™ ag凯发k8真人娱乐 Monotherapy and in Combination with Toripalimab (Tori; Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors
Date: Thursday, November 10, 2022 (abstract publication on November 7)
Poster Session: 9:00 a.m. – 9:00 p.m. Eastern Time (ET)
Onsite Location: Poster Hall
Abstract Poster Number: 753
. Title: A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of an Anti-CTLA-4 NEObody™ ag凯发k8真人娱乐 in Combination with Pembrolizumab (Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors: A Preliminary Update
Date: Thursday, November 10, 2022 (abstract publication on November 7)
Poster Session: 9:00 a.m. – 9:00 p.m. ET
Onsite Location: Poster Hall
Abstract Poster Number: 773

Both posters will be published on the company’s website at www.adagene.com/pipeline/publications in accordance with the SITC embargo policy on November 10, 2022.

About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody®, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

For more information, please visit:https://investor.adagene.com. Follow Adagene onWeChat,LinkedIn and Twitter.

SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.